A novel Ex Vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Cartellieri, Marc ^a,b   Koristka, Stefanie ^a   Arndt, Claudia ^a   Feldmann, Anja ^a,b   Stamova, Slava ^a   Von Bonin, Malte ^c   Töpfer, Katrin ^a   Krüger, Thomas ^a   Geib, Mathias ^a   Michalk, Irene ^a   Temme, Achim ^a   Bornhäuser, Martin ^c,d   Lindemann, Dirk ^a,d   Ehninger, Gerhard ^c   Bachmann, Michael P ^a,b,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; MONOCLONAL ANTIBODY; PROSTATE STEM CELL ANTIGEN; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL EXPANSION; CELL ISOLATION; CELL SELECTION; CONTROLLED STUDY; DNA MODIFICATION; DRUG BINDING SITE; ENGRAFTMENT; EPITOPE MAPPING; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; T LYMPHOCYTE; ADOPTIVE TRANSFER; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; EPITOPES; HUMANS; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN; T-LYMPHOCYTES;

EID: 84899432342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093745     Document Type: Article

References (50)

1. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol: 12[4]: 269-281.
2. Turtle CJ, Hudecek M, Jensen MC, Riddell SR (2012) Engineered T cells for anti-cancer therapy. Curr Opin Immunol: 24[5]: 633-639.
3. Brenner MK, Heslop HE (2010) Adoptive T cell therapy of cancer. Curr Opin Immunol: 22[2]: 251-257.
4. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, et al. (2010) Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol: e-pub doi: 10.1155/2010/956304.
5. Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, et al. (2011) Tumor evasion from T cell surveillance. J Biomed Biotechnol: e-pub doi: 10.1155/2011/918471.
6. Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol: 172[1]: 104-113. (Pubitemid 38020461)
7. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, et al. (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol: 167[11]: 6123-6131. (Pubitemid 33081538)
8. Koehler H, Kofler D, Hombach A, Abken H (2007) CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res: 67[5]: 2265-2273. (Pubitemid 46424246)
9. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol: 20[1]: 70-75. (Pubitemid 34044918)
10. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, et al. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest: 121[5]: 1822-1826.
11. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, et al. (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood: 96[3]: 785-793. (Pubitemid 30616838)
12. Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, et al. (1994) Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood: 84[9]: 2878-2889. (Pubitemid 24328074)
13. Elinav E, Waks T, Eshhar Z (2008) Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology: 134[7]: 2014-2024. (Pubitemid 351783252)
14. Elinav E, Adam N, Waks T, Eshhar Z (2009) Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology: 136[5]: 1721-1731.
15. Hombach AA, Kofler D, Rappl G, Abken H (2009) Redirecting human CD4+ CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity. Gene Ther: 16[9]: 1088-1096.
16. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood: 118[18]: 4817-4828.
17. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med: 3[95]: e-pub doi: 10.1126/scitranslmed.3002842.
18. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood: 119[12]: 2709-2720.
19. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med: 365[8]: 725-733.
20. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, et al. (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother: 32[2]: 169-180.
21. Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, et al. (2010) Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods: 355[1-2]: 52-60.
22. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, et al. (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med: 9[3]: 279-286. (Pubitemid 36362782)
23. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, et al. (2002) Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol: 20[2]: 143-148. (Pubitemid 34158029)
24. Grigorian A, Torossian S, Demetriou M (2009) T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev: 230[1]: 232-246.
25. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, et al. (2013) Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun: 42: 105-116.
26. Dannull J, Diener PA, Prikler L, Furstenberger G, Cerny T, et al. (2000) Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 60: 5522-5528.
27. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, et al. (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol: 53[4]: 694-708.
28. Walter RB, Appelbaum FR, Estey EH, Bernstein ID (2012) Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood: 119[26]: 6198-6208.
29. Feldmann A, Arndt C, Topfer K, Stamova S, Krone F, et al. (2012) Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells. J Immunol: 189[6]: 3249-3259.
30. Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, et al. (2007) Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate: 67[10]: 1121-1131. (Pubitemid 46983341)
31. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, et al. (2013) Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia: e-pub ahead of print doi: 10.1038/leu.2013.243.
32. Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, et al. (2013) Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia: 27[4]: 964-967.
33. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, et al. (2011) Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia: 25[6]: 1053-1056.
34. Hombach AA, Holzinger A, Abken H (2013) The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells. Curr Mol Med: 13[7]: 1079-1088.
35. Finney HM, Lawson AD, Bebbington CR, Weir AN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol: 161[6]: 2791-2797. (Pubitemid 28425698)
36. Davila ML, Brentjens R, Wang X, Riviere I, Sadelain M (2012) How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology: 1[9]: 1577-1583.
37. Suerth JD, Schambach A, Baum C (2012) Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol: 24[5]: 598-608.
38. De Oliveira SN, Ryan C, Giannoni F, Hardee CL, Tremcinska I, et al. (2013) Modification of Hematopoietic Stem/Progenitor Cells with CD19-Specific Chimeric Antigen Receptors as a Novel Approach for Cancer Immunotherapy. Hum Gene Ther: 24[10]: 824-839.
39. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, et al. (2013) Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol: 31[10]: 928-933.
40. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, et al. (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther: 17[8]: 1453-1464.
41. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest: 118[1]: 294-305.
42. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, et al. (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A: 102[27]: 9571-9576. (Pubitemid 40981722)
43. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, et al. (2011) A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood: 118[5]: 1255-1263.
44. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol: 31[1]: 71-75.
45. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, et al. (2011) Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate: 71[9]: 998-1011.
46. Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, et al. (2011) Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol: 49[3]: 474-482.
47. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol: 22[5]: 589-594. (Pubitemid 38585911)
48. Ho YP, Schnabel V, Swiersy A, Stirnnagel K, Lindemann D (2012) A small-molecule-controlled system for efficient pseudotyping of prototype foamy virus vectors. Mol Ther: 20[6]: 1167-1176.
49. Stirnnagel K, Luftenegger D, Stange A, Swiersy A, Mullers E, et al. (2010) Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles. Retrovirology: 7: 45-47.
50. von Bonin M, Wermke M, Cosgun KN, Thiede C, Bornhauser M, et al. (2013) In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. PLoS One: 8[4]: e60680.